kinesin family member 4AGenealiases: KIF4 · KIF4G1 · MRX100 · TMDI · XLID100
Q-omics provides the consensus-scored KIF4A profile across patient tissues and cancer cell-line models. KIF4A expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, KIF4A is differentially expressed in 18, with the highest sampling consensus in HNSC. Additionally, KIF4A protein abundance shows 28,062 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, HNSC, and LUAD as cancer lineages where KIF4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF4A survival associations across molecular data types. KIF4A RNA expression shows survival associations in the most cancer types (29), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF4A RNA expression–survival associations across cancer types. High KIF4A expression shows unfavorable associations in KIRP, ACC, MESO, KIRC, KICH and LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for KIF4A RNA expression.
This table summarizes KIF4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 18, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KIF4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF4A shows higher tumor expression in HNSC, LUAD, BLCA, KIRP, COAD and KIRC. The HNSC box plot shows higher KIF4A RNA expression in tumor versus normal tissue (log2 FC = +2.302, t-test p < 0.001).
This table shows molecular features associated with KIF4A in patient tissues and cancer cell lines. In patient samples, KIF4A shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and OVARY.
